WO2009072624A1 - ヘテロ環化合物による造血幹細胞の増幅方法 - Google Patents

ヘテロ環化合物による造血幹細胞の増幅方法 Download PDF

Info

Publication number
WO2009072624A1
WO2009072624A1 PCT/JP2008/072188 JP2008072188W WO2009072624A1 WO 2009072624 A1 WO2009072624 A1 WO 2009072624A1 JP 2008072188 W JP2008072188 W JP 2008072188W WO 2009072624 A1 WO2009072624 A1 WO 2009072624A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
positive cell
hematopoietic stem
stem cell
cell
Prior art date
Application number
PCT/JP2008/072188
Other languages
English (en)
French (fr)
Inventor
Takanori Nakamura
Atsushi Miyamura
Taito Nishino
Norihisa Ishiwata
Katsuaki Miyaji
Original Assignee
Nissan Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Industries, Ltd. filed Critical Nissan Chemical Industries, Ltd.
Priority to US12/746,497 priority Critical patent/US20100310536A1/en
Priority to EP08858273A priority patent/EP2228435A4/en
Priority to JP2009544752A priority patent/JP5573159B2/ja
Publication of WO2009072624A1 publication Critical patent/WO2009072624A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　本発明は、生物学的に安全かつ廉価にて製造可能な低分子化合物を利用し、ＣＤ３４陽性細胞を生体外で従来よりも効率的かつ短期間に増幅することを課題とする。本発明のさらなる課題は、造血幹細胞及び／又は造血前駆細胞の機能不全に伴う各種の造血系疾患に対する治療方法として有用である、ＣＤ３４陽性細胞の増幅剤を提供することにある。 　式（Ｉ）（式中の、Ａ、Ｂ、Ｌ１、Ｌ２、Ｌ３、Ｌ４、Ｒ１、Ｒ２、Ｒ３、Ｘ及びＹは、本文中において定義される。）で表される化合物、該化合物の互変異性体若しくはその医薬的に許容され得る塩又はそれらの溶媒和物の存在下、ＣＤ３４陽性細胞を生体外で培養することを特徴とするＣＤ３４陽性細胞の増幅方法。
PCT/JP2008/072188 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法 WO2009072624A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/746,497 US20100310536A1 (en) 2007-12-05 2008-12-05 Method for expanding hematopoietic stem cells using heterocyclic compound
EP08858273A EP2228435A4 (en) 2007-12-05 2008-12-05 METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
JP2009544752A JP5573159B2 (ja) 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007315165 2007-12-05
JP2007-315165 2007-12-05

Publications (1)

Publication Number Publication Date
WO2009072624A1 true WO2009072624A1 (ja) 2009-06-11

Family

ID=40717802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072188 WO2009072624A1 (ja) 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法

Country Status (4)

Country Link
US (1) US20100310536A1 (ja)
EP (1) EP2228435A4 (ja)
JP (1) JP5573159B2 (ja)
WO (1) WO2009072624A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140685A1 (ja) * 2009-06-04 2010-12-09 日産化学工業株式会社 ヘテロ環化合物及び造血幹細胞の増幅剤
JPWO2009072625A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072626A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
WO2012074068A1 (ja) * 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
WO2013051625A1 (ja) 2011-10-03 2013-04-11 日産化学工業株式会社 多能性幹細胞からの巨核球及び／又は血小板の製造方法
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health Inc PERMEATION OF WHOLE VERTEBRAL BODY WITH CRYOPROTECTIVE USING VACUUM-ASSISTED DIFFUSION
EP4228406A1 (en) 2020-10-14 2023-08-23 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
CN117279650A (zh) 2020-12-18 2023-12-22 奥瑟姆健康公司 细胞治疗方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502617A (ja) 1998-02-17 2002-01-29 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
JP2006506452A (ja) * 2002-10-09 2006-02-23 日産化学工業株式会社 ピラゾロン化合物及びトロンボポエチンレセプター活性化剤
JP2006061106A (ja) 2004-08-27 2006-03-09 Hiroo Iwata 造血幹細胞の製造方法
WO2006062247A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換複素環化合物及びトロンボポエチンレセプター活性化剤
WO2006062240A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006062249A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2006064957A1 (ja) 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
JP2006527187A (ja) * 2003-06-06 2006-11-30 日産化学工業株式会社 ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2007052808A1 (ja) * 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007142308A1 (ja) * 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314461T1 (de) * 1998-02-05 2006-01-15 Novartis Pharma Gmbh Vermehrte und genetisch modifizierte populationen menschlicher hämatopoitischer stammzellen
US20030044978A1 (en) * 1998-02-05 2003-03-06 Novartis Corporation Expanded and genetically modified populations of human hematopoietic stem cells
KR20040023724A (ko) * 2001-08-07 2004-03-18 기린 비루 가부시키가이샤 조혈 간세포의 제조법
WO2009072626A1 (ja) * 2007-12-05 2009-06-11 Nissan Chemical Industries, Ltd. ヘテロ環化合物による造血幹細胞の増幅方法
JP5573160B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502617A (ja) 1998-02-17 2002-01-29 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
JP2006506452A (ja) * 2002-10-09 2006-02-23 日産化学工業株式会社 ピラゾロン化合物及びトロンボポエチンレセプター活性化剤
JP2006527187A (ja) * 2003-06-06 2006-11-30 日産化学工業株式会社 ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
JP2006061106A (ja) 2004-08-27 2006-03-09 Hiroo Iwata 造血幹細胞の製造方法
WO2006062247A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換複素環化合物及びトロンボポエチンレセプター活性化剤
WO2006062240A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006062249A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2006064957A1 (ja) 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
WO2007052808A1 (ja) * 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007142308A1 (ja) * 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ASTORI G, BONE MARROW TRANSPLANT, vol. 35, 2005, pages 1101
CASSEL, A. ET AL., EXP. HEMATOL., vol. 21, 1993, pages 585 - 91
CHUTE, JP ET AL., PROC NATL ACAD SCI USA., vol. 103, 2006, pages 11707 - 12
CWIRLA, S.E. ET AL.: "Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine", SCIENCE, vol. 276, no. 5319, 1997, pages 1696 - 1699, XP008136351 *
EMA, H. ET AL., BLOOD, vol. 75, 1990, pages 1941 - 6
ISHIZAWA, L. ET AL., J HEMATOTHER., vol. 2, 1993, pages 333 - 8
KAUSHANSKY, K ET AL., ANN NY ACAD SCI., vol. 1044, 2005, pages 139 - 141
KOLLER MR, BONE MARROW TRANSPLANT, vol. 21, 1998, pages 653
KOLLER, MR, BLOOD, vol. 82, 1993, pages 378
KURTZBERT, J. ET AL., NEW ENG. J. MED., vol. 335, 1996, pages 157 - 66
LAM AC ET AL., TRANSFUSION, vol. 41, no. 12, December 2001 (2001-12-01), pages 1567 - 76
LEUNG, AY ET AL., EXP HEMATOL., vol. 33, 2005, pages 422 - 7
LIU, J. ET AL.: "Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow", BONE MARROW TRANSPLANT., vol. 24, no. 3, 1999, pages 247 - 252, XP008136342 *
LU, L. ET AL., EXP. HEMATOL., vol. 11, 1983, pages 721 - 9
MILHEM, M ET AL., BLOOD., vol. 103, 2004, pages 4102 - 10
NAKAMURA, T. ET AL.: "A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis", BLOOD, vol. 107, no. 11, 2006, pages 4300 - 4307, XP008136356 *
ORLIC, D ET AL., NATURE, vol. 410, 2001, pages 701 - 5
ROSLER, E ET AL., EXP HEMATOL., vol. 28, 2000, pages 841 - 52
SCHWARTZ RM, PROC. NATL. ACAD. SCI. U.S.A., vol. 88, 1991, pages 6760
See also references of EP2228435A4 *
SHIMAKURA, Y ET AL., STEM CELLS, vol. 18, 2000, pages 183 - 9
TAGUCHI, A ET AL., J CLIN INVEST., vol. 114, 2004, pages 330 - 8
TATEISHI-YUYAMA, E ET AL., LANCET, vol. 360, 2002, pages 427 - 35

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5573160B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072625A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072626A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
US9115341B2 (en) 2007-12-05 2015-08-25 Nissan Chemical Industries, Ltd. Method for expanding hematopoietic stem cells using heterocyclic compound
JP5573161B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
EP2439204A1 (en) * 2009-06-04 2012-04-11 Nissan Chemical Industries, Ltd. Heterocyclic compound and hematopoietic stem cell amplifier
WO2010140685A1 (ja) * 2009-06-04 2010-12-09 日産化学工業株式会社 ヘテロ環化合物及び造血幹細胞の増幅剤
EP2439204A4 (en) * 2009-06-04 2012-06-20 Nissan Chemical Ind Ltd HETEROCYCLIC CONNECTION AND HEMATOPOIETIC STEM CELL AMPLIFIER
US9328085B2 (en) 2009-06-04 2016-05-03 Nissan Chemical Industries, Ltd. Heterocyclic compounds and expansion agents for hematopoietic stem cells
WO2012074068A1 (ja) * 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
US9212348B2 (en) 2010-12-01 2015-12-15 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compounds
JP5946775B2 (ja) * 2010-12-01 2016-07-06 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
KR20140082673A (ko) 2011-10-03 2014-07-02 닛산 가가쿠 고교 가부시키 가이샤 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법
WO2013051625A1 (ja) 2011-10-03 2013-04-11 日産化学工業株式会社 多能性幹細胞からの巨核球及び／又は血小板の製造方法
JP2014226079A (ja) * 2013-05-22 2014-12-08 国立大学法人九州大学 Ｎｋ細胞の調製方法
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法

Also Published As

Publication number Publication date
JPWO2009072624A1 (ja) 2011-04-28
US20100310536A1 (en) 2010-12-09
EP2228435A1 (en) 2010-09-15
JP5573159B2 (ja) 2014-08-20
EP2228435A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
WO2009072624A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2009072626A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2009072625A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
SG179207A1 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MX356756B (es) Células madre pluripotentes en microportadores.
WO2009072635A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
TW200732306A (en) Pyrimidine derivatives
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
IN2012DN00755A (ja)
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
WO2008079787A3 (en) Glucokinase activators
ATE508747T1 (de) C-kit kinase-hemmer
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
NZ579928A (en) Fluorinated derivatives of deferiprone
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
NZ625593A (en) Purine derivatives useful as hsp90 inhibitors
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
HK1125291A1 (en) Method of using guava extract and composition including guava extract
WO2008114812A1 (ja) Jak阻害剤
WO2007143117A3 (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08858273

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544752

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2008858273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008858273

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12746497

Country of ref document: US